ATE422361T1 - Crfr1 selektive liganden - Google Patents

Crfr1 selektive liganden

Info

Publication number
ATE422361T1
ATE422361T1 AT02752639T AT02752639T ATE422361T1 AT E422361 T1 ATE422361 T1 AT E422361T1 AT 02752639 T AT02752639 T AT 02752639T AT 02752639 T AT02752639 T AT 02752639T AT E422361 T1 ATE422361 T1 AT E422361T1
Authority
AT
Austria
Prior art keywords
crfr1
selective ligands
bind
crf
analogs
Prior art date
Application number
AT02752639T
Other languages
English (en)
Inventor
Jean Rivier
Wylie Vale
Marilyn Perrin
Jozsef Guylas
Original Assignee
Salk Inst For Biological Studi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi
Application granted granted Critical
Publication of ATE422361T1 publication Critical patent/ATE422361T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT02752639T 2001-08-01 2002-07-30 Crfr1 selektive liganden ATE422361T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30950401P 2001-08-01 2001-08-01

Publications (1)

Publication Number Publication Date
ATE422361T1 true ATE422361T1 (de) 2009-02-15

Family

ID=23198502

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02752639T ATE422361T1 (de) 2001-08-01 2002-07-30 Crfr1 selektive liganden

Country Status (9)

Country Link
US (2) US7498300B2 (de)
EP (1) EP1572679B1 (de)
JP (1) JP4163106B2 (de)
AT (1) ATE422361T1 (de)
AU (1) AU2002355742A1 (de)
CA (1) CA2455223C (de)
DE (1) DE60231157D1 (de)
ES (1) ES2322133T3 (de)
WO (1) WO2003011823A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE422361T1 (de) * 2001-08-01 2009-02-15 Salk Inst For Biological Studi Crfr1 selektive liganden
WO2005073249A1 (en) * 2004-01-19 2005-08-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Corticotropin-releasing factor receptor 1 (crfr1) agonist polypeptides
US8193250B2 (en) 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
CA2822442C (en) 2010-12-22 2021-03-16 The Salk Institute For Biological Studies Cyclic crf antagonist peptides
WO2013063046A1 (en) 2011-10-24 2013-05-02 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
WO2018075973A2 (en) * 2016-10-20 2018-04-26 Cortene Inc. Methods of treating diseases resulting from a maladapted stress response

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489163A (en) * 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US4605642A (en) * 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5109111A (en) * 1988-09-23 1992-04-28 The Salk Institute For Biological Studies CRF antagonists
US5245009A (en) * 1990-03-23 1993-09-14 The Salk Institute For Biological Studies CRF antagonists
US5493006A (en) * 1993-06-16 1996-02-20 The Salk Institute For Biological Studies Cyclic CRF analogs
US5663292A (en) * 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US6326463B1 (en) * 1994-12-12 2001-12-04 The Salk Institute For Biological Studies Cyclic CRF agonists
US5824771A (en) * 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5777073A (en) * 1994-12-12 1998-07-07 The Salk Institute For Biological Studies Cyclic CRF antagonist peptides
US6214797B1 (en) * 1995-06-13 2001-04-10 The Salk Institute For Biological Studies Urocortin peptides, nucleic acid encoding same methods for using same
US6323463B1 (en) * 2000-03-29 2001-11-27 Applied Materials, Inc. Method and apparatus for reducing contamination in a wafer loadlock of a semiconductor wafer processing system
ATE422361T1 (de) * 2001-08-01 2009-02-15 Salk Inst For Biological Studi Crfr1 selektive liganden

Also Published As

Publication number Publication date
CA2455223C (en) 2010-11-16
ES2322133T3 (es) 2009-06-17
EP1572679A2 (de) 2005-09-14
AU2002355742A8 (en) 2007-11-01
US20040204564A1 (en) 2004-10-14
WO2003011823A2 (en) 2003-02-13
AU2002355742A1 (en) 2003-02-17
EP1572679A4 (de) 2008-01-23
CA2455223A1 (en) 2003-02-13
US7851588B2 (en) 2010-12-14
JP2005510458A (ja) 2005-04-21
EP1572679B1 (de) 2009-02-11
JP4163106B2 (ja) 2008-10-08
DE60231157D1 (de) 2009-03-26
US20090149629A1 (en) 2009-06-11
US7498300B2 (en) 2009-03-03
WO2003011823A3 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
NO2017028I2 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
IL232501A0 (en) Stable analogs of medicinal peptides and polypeptides
DE502005006284D1 (de) Keratin-bindende polypeptide
EA200700292A1 (ru) Полипептиды с повышенной экспрессией
DK1761553T3 (da) MHC molecule-binding tumor-associated peptides
WO2001064835A8 (en) Novel nucleic acids and polypeptides
BR0212363A (pt) Expressão hìbrida e em tandem de proteìnas de neisseria
CY1112198T1 (el) Αναλογα κομπστατινης με βελτιωμενη δραστικοτητα
DK1765860T3 (da) Ny-ESO-T.cellereceptor med höj affinitet
HUP0303246A2 (hu) Aktív fehérjék fokozott kinyerése
ATE405654T1 (de) Polypeptid mit verbesserter cytosin-deaminase- aktivität
DE602004001727D1 (de) Verfahren zur herstellung cyclischer peptide
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado
ATE422361T1 (de) Crfr1 selektive liganden
DK1897552T3 (da) Polymer-konjugeret glycosyleret neublastin
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
ATE394482T1 (de) Verfahren und zusammensetzungen für peptid-, protein- und peptidomimetische synthese
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
KR930701487A (ko) 식물성 독소 겔로닌의 단백질 구조물
DE60221805D1 (de) Peptide mit affinität zu gp120, und ihre verwendungen
CA2380216A1 (en) Use of interleukin-18 inhibitors to inhibit tumor metastasis
DE60031422D1 (de) Peptidanaloge als selektive inhibitoren der thrombinaktivierung des durch protease aktivierten rezeptors
DE60139770D1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
TR200103240T2 (tr) Endoparazit öldürücü bileşimler.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties